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The in vitro study of tetracannabinolic acid (THCA) derivatives ALAM027 
and ALAM108 was carried out on the following human tumor cells: 
T47D (breast, ductal carcinoma), PC-3 (prostate, adenocarcinoma), HT-
29 (colorectal carcinoma), Caco-2 (colon, adenocarcinoma), A549 (lung, 
carcinoma), U87MG (human glioblastoma) and U266B1 (multiple 
myeloma).
The in vitro effects of THCA derivatives ALAM027 and ALAM108 on cell 
growth inhibition and IC50 values were measured using the CellTiter Glo 
assay. 
The ALAM027 compound showed good growth inhibition in all cell lines 
tested with the exception of U87MG cells. The ALAM108 compound also 
suppressed the growth of U87 MG cells but had little effect on T47D tumor 
cells. 
In vitro studies of THCA derivatives ALAM027 and ALAM108 showed 
antitumor activity in all cell lines tested. The difference in the activity of 
these compounds in relation to the T47D and U87MG tumor cells may be 
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1. Introduction
Tetrahydrocannabinolic acid (THCA) is the main com-
ponent of Cannabis sativa. However, in contrast to its 
derivative THC, the biological properties of THCA have 
been studied to a much lesser extent, particularly because 
it is difficult to isolate and because of its high sensitivity 
to heat and UV radiation. A convenient and inexpensive 
method has recently been described to isolate this acid us-
ing ion-exchange resins, opening up the way to industrial 
scale production and making THCA a suitable starting 
product for drug synthesis [1,2]. This advance has recent-
ly facilitated the synthesis of two THCA derivatives, 
ALAM027 and ALAM108, which exhibit good anti-tumor 
activity in PANC-1 and AsPC-1 cell lines [3]. 
Since natural cannabinoids such as THC and CBD are 
known to have broad-spectrum anti-tumor activity against 
many types of tumors [4-6], it is of interest to investigate 
a potential effect of ALAM027 and ALAM108 on var-
ious types of cancer cells. According to World Health 
Organization data the most widespread types of cancers 
are breast, lung, colon, intestine, pancreatic, prostate tum-
ors and blood diseases such as multiple myeloma. Brain 
tumors such as gliomas are also potentially interesting, 
particularly because of their aggressive and highly inva-
sive properties [7]. To facilitate comparisons between pre-
viously reported activities of natural cannabinoids and the 
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ALAM027 and ALAM108 compounds, the current study 
examines the effects of these compounds on the following 
human cancer cell lines: T47D (breast, ductal carcinoma), 
PC-3 (prostate, adenocarcinoma), HT-29 (colorectal car-
cinoma), Caco-2 (colon, adenocarcinoma), A549 (lung, 
carcinoma), U87MG (human glioblastoma) and U266B1(-
multiple myeloma).
All these tumor cell lines express significant levels of 
CB1 and CB2 receptors in their cell membrane and this 
amount increases with cell proliferation. Thus, several 
articles have been devoted to studying the effects of THC 
and CBD on tumor cell line T47D which is often used in 
breast cancer research [8-11]. 
The PC-3 cell line is also often used in prostate cancer 
research. Studies examining the effects of cannabinoids 
on PC-3 cells have predominantly focused on elucidating 
tumor growth suppression mechanisms [12,13]. 
The HT-29 cell line is a colorectal tumor line which is 
often used as an epithelial cell model to study new drug 
candidates because of its ability to differentiate. Cannab-
inoids have a significant effect on HT-29 cells as they in-
duce cell death through apoptosis and inhibit proliferation 
[14]. The role of cannabinoid receptors in these processes 
has been studied by examining effects of agonists such 
as THC and CBD on cancer cells in the presence and ab-
sence of CB1 and CB2 antagonists [15]. 
Similarly to HT-29 cells, natural cannabinoids also sup-
press colorectal adenocarcinoma Caco-2 cell growth by 
inducing apoptosis and inhibiting cell proliferation which 
is mediated through CB1 receptor binding [16,17].
A549 is one of the most widely studied lung tumor 
cell line, which is often used as a testing ground for new 
drugs, such as natural and synthetic cannabinoids because 
the main determining factor of the anticancer effect of 
these cannabinoids on A549 cells is their ability to block 
the CB1 receptor, which is overexpressed in non-small 
cell lung tumors [18-20].
Brain glioblastoma occupies an important place among 
studies of the anticancer activity of cannabinoids. A sig-
nificant number of research studies have focused on the 
effects of THC and CBD ligands on U87 MG, in particu-
lar because of their rather substantial in vitro and in vivo 
activities [21-23]. It is interesting to note that, in contrast to 
SF126 glioblastoma cells, in the case of U87MG cells 
THC does not exhibit a pleiotropic effect at 1 µM concen-
tration and below [21]. Multiple myeloma is one of the most 
serious hematological diseases and is characterized by 
drug resistance. Cannabinoids are among the most prom-
ising candidates for the treatment of this disease. Recent 
research [24] indicates that the IC50 values for CBD and 
THC in U266 cells are 19.8 µM and 39.5 µM respectively, 
and their combined use leads to the synergistic increase of 
cytotoxic effects when compared to their individual activ-
ities. 
The present activity study of the ALAM027 and 
ALAM108 compounds in these selected tumor cell lines 
will not only allow to assess their anticancer activity but 
also, to a certain extent, could be used to understand their 
putative functional mechanisms.
2. Materials and Methods
Synthesis data and spectral characteristics of THCA de-
rivatives ALAM027 and ALAM108 have been described 
previously [8]. The in vitro study was performed on T47D, 
PC-3, HT-29, Caco-2, A549, U87MG and U266B1 cells 
obtained from the Chempartner (China) collection using 
the CellTiter Glo Viability Assay. Cells were seeded in 96-
well plates in a volume of 100 μl per well, according to 
the planned plate layout and a predefined seeding density. 
Plates were incubated in a CO2 incubator overnight. The 
compound stock solution was diluted with DMSO to a 200 
× final concentration, and serial 3-fold dilutions prepared 
from a 2-mM solution (final concentration range: 0.5-
10000 nM for 10 doses). An internal staurosporine control 
was included on each plate. A volume of 0.5 μl of diluted 
compound was added to appropriate wells according to 
the plate layout. The plates were incubated at 5% CO2, 
37°C for 72 hours. After this incubation, CellTiter-Glo re-
agents were prepared and added, and the plates read in an 
Envision plate reader. Inhibition and IC50 for each of the 
compounds were calculated with the XLFit curve fitting 
software (n=2, Z Factor, SW). 
3. Results and Discussions
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Figure 1. Growth inhibition curves of T47D, PC-3, HT-29, Caco-2, A549, U87MG and U266B1 cells at a wide range of 
THCA, ALAM027, and ALAM108 concentrations.
and ALAM108 are shown below.
The growth inhibition curves of T47D, PC-3, HT-29, 
Caco-2, A549, U47MG and U266B1 tumor cells as a 
function of THCA, ALAM027 and ALAM108 concentra-
tions are shown in Figure 1.
Compared to its derivatives the level of THCA growth 
inhibition, was generally low for all cell lines examined 
but THCA did tend to inhibit T47D, A549 and U87MG 
cell proliferation to a greater extent than the other lines 
(Table 1).
For the T47D cell line, the ALAM027 compound shows 
good growth inhibition with an IC50 value comparable 
to THC (6.7 µM) and CBD (5 µM) [8]. The ALAM108 
compound is less active, though its ability to inhibit cell 
proliferation significantly exceeds that of THCA.
The inhibition values of both cannabinoids on PC-3 
prostate tumor cells are very similar (Table 1) but the 
ALAM027 compound yields a pleiotropic effect at 1 µM 
concentration following the growth inhibition. 
The comparison of both cannabinoid activities in 
DOI: https://doi.org/10.30564/jor.v3i2.3629
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HT-29 cells shows that these cells are more sensitive to 
ALAM108 than to ALAM027 while IC50 values of both 
compounds are much higher than those of CBD (23-30 
µM) and THC (30 µM) [14]. However, in the case of Caco-
2 cells the IC50 values differ slightly and are comparable 
to those obtained in PC-3 cells.
The effect of ALAM027 and ALAM108 on A549 cells 
is practically the same both in terms of the degree of inhi-
bition and IC50. When compared to THC (27.2 µM) and 
CBD (37.1µM) [19] this advantage becomes clearly evi-
dent. 
Regarding the U87MG cell line, compound ALAM027 
shows a low-level activity comparable to THCA. Cannab-
inoid ALAM108 effectively inhibits cell survival with an 
IC50 of 3.37 µM that is on par with the activity of THC 
(IC50 1.2-14 µM) and CBD (IC50 1.5-9.7 µM) in this cell 
line [21]. One of the possible reasons may be the ability of 
ALAM108 to pass through the blood-brain barrier due 
to its greater hydrophobicity (LogP 5.81) compared to 
ALAM027 (LogP 4.38). Perhaps this assumption is very 
relative, but currently available cannabinoid anticancer 
activity data on U87MG cells only relates to THC, CBD 
and some synthetic cannabinoids like WIN55,212-2 [19-23].
The comparison of both cannabinoid activity against 
U266B1 cells shows the advantage of ALAM108 as for 
other cell lines.
Table 1. IC50 and inhibition values (10 µM) of THCA 
and its derivatives on T47D, A549, PC-3, HT-29, Caco-2, 






















T47D 18.20 >10 97.90 5.52 47.20 >10 0.86 20.42
U87MG 10.52 >10 19.84 >10 73.80 3.37 0.93 45.37
A549 9.30 >10 77.08 5.59 70.01 5.53 0.83 17.22
PC-3 15.43 >10 61.13 9.94 63.61 7.45 0.81 12.68
HT-29 16.77 >10 86.21 6.27 88.13 1.99 0.85 18.99
Caco-2 12.99 >10 60.81 8.87 67.16 6.56 0.80 13.02
U266B1 8.68 >10 58.33 8.20 73.05 4.52 0.88 25.03
* [25]
4. Conclusions
Our current in vitro study of THCA derivatives 
ALAM027 and ALAM108 showed their antitumor activ-
ity in all the tumor cell types examined. The difference in 
the activity of these compounds in relation to the T47D 
and U87MG tumor cells may be indicative of different 
functional mechanisms.
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